Limaprost

Summary

Limaprost (CHEMBL2107456) is a phase-3 clinical-stage small molecule (ATC B01AC28); indicated across 2 conditions including spinal cord disorder and thrombotic disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: B01AC28
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 380.5 Da · C22H36O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107456
Name	Limaprost
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6438378
ATC	B01AC28
Molecular formula	C22H36O5
Molecular weight	380.5
InChIKey	OJZYRQPMEIEQFC-UAWLTFRCSA-N

SMILES: CCCC[C@H](C)C[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCC/C=C/C(=O)O)O)O

IUPAC name: (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]hept-2-enoic acid

Also known as: Limaprost, Limaprost alfadex, LIMAPROST, limaprost

Patent coverage: 377 distinct patent families (1,280 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
spinal cord disorder	3	MONDO:0002545	HP:0002196
thrombotic disease	3	MONDO:0000831	HP:0004419

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01888536	PHASE4	COMPLETED	A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis
NCT02125981	PHASE3	COMPLETED	The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).